Why Is AVEANNA HEALTHCARE H (AVAH) Stock Up Today?

Why AVAH stock is up today

Aveanna Healthcare Holdings Inc. stock surged 24.75% to $11.29 on August 13, 2026, driven by the company's better-than-expected second-quarter earnings report and an upward revision of its full-year 2026 guidance. The stock hit a five-year high amid strong revenue growth and improved profitability, which reinforced positive sentiment among investors.

What Happened

Aveanna Healthcare reported second-quarter 2026 non-GAAP earnings per share of $0.22, beating the $0.17 estimate. Revenue for the quarter reached $670.48 million, surpassing the $638.619 million forecast and growing 13.7% year-over-year. The company raised its full-year 2026 revenue guidance, now expecting more than $2.68 billion compared to the prior $2.625 billion estimate. The earnings report highlighted double-digit revenue growth, strong cash flow, and segment performance that exceeded expectations. Truist Securities also adjusted its price target for the stock to $11, maintaining a Hold rating. These developments reinforced the stock’s appeal, particularly as the company continues to expand its market position in home healthcare services.

What The Data Shows

The stock’s 24.75% move pushed it to a new 52-week high of $11.29, significantly above its previous high of $10.32. The company’s fundamentals remain strong, with a trailing twelve-month revenue growth of 20.5% and a net margin of 10.4%. The stock trades at a P/E ratio of 7.2, suggesting it remains attractively valued relative to its earnings. Additionally, the stock’s beta of 1.93 indicates it is more volatile than the broader market. Recent insider transactions show $215.6 million in sales over the last 90 days, with no insider buying reported, which may reflect a shift in ownership or strategy among key stakeholders.

What To Watch

The company’s Q2 2026 earnings call transcript was released on August 13, offering further insight into management’s outlook and operational performance. Investors should monitor the full transcript and any follow-up analyst commentary for additional signals on the company’s trajectory.